Revance Therapeutics, Inc.
RVNCDelisted Feb 6, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001479290
Revance Therapeutics, Inc. was delisted on Feb 6, 2025; its insiders filed their last Form 4 on Feb 6, 2025; 174 institutions reported holding it in 13F filings for Q4 2024, worth $249.2M in total; Fairfax Financial was the only superinvestor holding it.
Superinvestors holding RVNC, Q4 2024
1 superinvestor reports holding Revance Therapeutics, Inc. on Form 13F, worth $64.1K in total. Weight is Revance Therapeutics, Inc.'s share of each 13F portfolio; actions compare shares with Q3 2024.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| Fairfax FinancialPrem Watsa | <0.1% | 21,158 | $64.1K | New |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of RVNC each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q4 2024
1 superinvestor holding at quarter end